{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Epithelial+Neoplasms&page=16", "query": { "condition": "Malignant Epithelial Neoplasms", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 12658, "total_pages": 1266, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Epithelial+Neoplasms&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Epithelial+Neoplasms&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T17:54:57.946Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03872947", "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Colorectal Cancer", "Cholangiocarcinoma", "Bladder Cancer", "Ovarian Cancer", "Gastric Cancer", "Palpable Subcutaneous Malignant Lesions", "Renal Cell Carcinoma", "Melanoma", "Epithelial Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "TRK-950", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Imiquimod Cream", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Toray Industries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2019-04-26", "completion_date": "2026-07-16", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-15T17:54:57.946Z", "location_count": 13, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03872947" }, { "nct_id": "NCT02405585", "title": "Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Carcinoma Non-resectable" ], "interventions": [ { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "Algenpantucel-L Immunotherapy", "type": "BIOLOGICAL" }, { "name": "SBRT", "type": "RADIATION" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-04", "completion_date": "2016-07-30", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-10-15T17:54:57.946Z", "location_count": 4, "location_summary": "Louisville, Kentucky • Burlington, Massachusetts • Albuquerque, New Mexico + 1 more", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02405585" }, { "nct_id": "NCT01302808", "title": "Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "Erlotinib plus Romidepsin (8 mg/m^2)", "type": "COMBINATION_PRODUCT" }, { "name": "Erlotinib plus Romidepsin (10 mg/m^2)", "type": "COMBINATION_PRODUCT" }, { "name": "Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis", "type": "COMBINATION_PRODUCT" }, { "name": "(Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2009-09", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2021-01-20", "last_synced_at": "2026-10-15T17:54:57.946Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01302808" }, { "nct_id": "NCT04258813", "title": "Onco-primary Care Networking to Support TEAM-based Care", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Blood Pressure", "Hypertension", "Cancer", "Cancer, Breast", "Cancer of Prostate", "Cancer Colorectal", "Cancer, Endometrial", "Cancer of Head and Neck", "Non Small Cell Lung Cancer", "CVD - Cardiovascular Disease", "Diabetes Mellitus", "Hypercholesterolemia", "Diabetes", "Cancer of Esophagus", "Cancer of Liver", "Cancer, Renal Cell", "Cancer of Pancreas", "Cancer Ovaries" ], "interventions": [ { "name": "iGuide Intervention (Self-guided)", "type": "BEHAVIORAL" }, { "name": "iGuide 2 Intervention (Tailored/Targeted)", "type": "BEHAVIORAL" }, { "name": "Control", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 313, "start_date": "2021-06-14", "completion_date": "2026-07-31", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-10-15T17:54:57.946Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04258813" }, { "nct_id": "NCT01847326", "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Tongue Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel albumin-stabilized nanoparticle formulation", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "hydroxyurea", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "hyperfractionated radiation therapy", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2013-03-26", "completion_date": "2024-01-22", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-15T17:54:57.946Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01847326" }, { "nct_id": "NCT07793578", "title": "Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Urothelial Carcinoma" ], "interventions": [ { "name": "capivasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2027-01-01", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-15T17:54:57.946Z", "location_count": 4, "location_summary": "West Haven, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "West Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07793578" }, { "nct_id": "NCT00612989", "title": "Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Temodar and O6-Benzylguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2005-02", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2014-07-16", "last_synced_at": "2026-10-15T17:54:57.946Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612989" }, { "nct_id": "NCT00767468", "title": "Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2008-10", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2012-05-23", "last_synced_at": "2026-10-15T17:54:57.946Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Durham, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00767468" }, { "nct_id": "NCT05929768", "title": "Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Early Stage Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2400, "start_date": "2023-09-15", "completion_date": "2033-04", "has_results": false, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-10-15T17:54:57.946Z", "location_count": 955, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 654 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05929768" }, { "nct_id": "NCT00054418", "title": "Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Osteoporosis" ], "interventions": [ { "name": "calcium carbonate", "type": "DIETARY_SUPPLEMENT" }, { "name": "vitamin D", "type": "DIETARY_SUPPLEMENT" }, { "name": "risedronate sodium", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 216, "start_date": "2003-03", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2016-07-13", "last_synced_at": "2026-10-15T17:54:57.946Z", "location_count": 198, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 124 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054418" } ] }